Research and Markets: Transitional Cell Cancer (Urothelial Cell Cancer) – Pipeline Review, H1 2012
Research and Markets has announced the addition of Global Markets Direct's new report "Transitional Cell Cance
New Drug Combination To Treat Lung Cancer
Cancer Research UK's Drug Development Office researchers develop new drug combination – vandetanib and selumetinib.
Cancer death rates fall among 50-somethings
Deaths from cancer in Britain have fallen 40% in people aged 50 to 59, according to figures produced by Cancer Research UK Deaths from cancer among 50-somethings have fallen to their lowest level in 40 years, thanks to better diagnosis, fewer people smoking and new drugs improving patients' chances of survival. In 1971 over 21,300 people in the UK aged between 50 and 59 died of cancer, but in …
ASCO '12 Abstract Dump: Cancer Stocks in Focus
BOSTON (TheStreet) — Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely watched annual meeting. Among the most significant cancer drug data unveiled for the first time Wednesday night came from phase III studies conducted by Aveo Pharmaceuticals and Exelixis, and …
Van Andel Research Institute And Dako Sign Agreement To License Cancer Diagnostic Tool
GRAND RAPIDS, Mich. and GLOSTRUP, Denmark, May 16, 2012 /PRNewswire/ – Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement …
FDA-approved drug makes established cancer vaccine work better
( University of Pennsylvania School of Medicine ) A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab.